Inside This Issue: Traumatic Brain Injury
Top News Alerts: Product Updates, Deals & Financings
Confernce Highlights: ASENT Annual Meeting
Company Spotlight: Banyan Biomarkers
Subscribe now to access over 30 articles covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Highlights: Valeant Makes a Grab for Cephalon, Targacept Builds Case for AstraZeneca License
Targacept (TRGT) was down about 7% after announcing mixed results from a Phase II ADHD study. The trial involved TC-5619, a highly selective alpha7 neuronal nicotinic receptor modulator that is subject to an option agreement with AstraZeneca (AZN). In the trial, conducted in non-smokers, TC-5619 did not meet the primary endpoint, change from baseline on the Conners’ ADHD Rating Scale after four, eight and twelve weeks of dosing. Some scales and assessments showed signs of activity, however, and the compound did best on the CAARS-S scale, a patient self-rating scale at 12 weeks. The company announced positive resutls in a separate Phase II for the same compound in cognitive dysfunction in schizophrenia in January. CEO J. Donald deBethizy expressed enthusiasm about the sum of the data to Neurotech Insights...
TBI: Defense Dollars Spur Development
One of the major driving forces behind traumatic brain injury (TBI) therapeutic and diagnostic programs is defense funding. Last year, according to John Reppas, Director of Public Policy at the Neurotechnology Industry Organization, the Department of Defense spent upwards of $800 million across a variety of funding mechanisms on TBI. It is a bit puzzling, however, where this money all goes and how to access it. It is often difficult to get detailed information about DoD investments and partnerships because the companies who are successful view their contacts and outreach to the DoD as part of their competitive intelligence... This article outlines traumatic brain injury, current treatments and drug, cell and device therapies in development ...
Banyan Biomarkers Turns Focus Toward TBI Field Test
Banyan Biomarkers, of Alachua Florida, was spun out of the University of Florida in 2003 by Ronald Hayes, PhD and Kevin Wang, PhD with a goal to use proteomics to develop biomarkers for acute brain injury. Traumatic brain injury (TBI) remains its main focus, although the company has since worked on biomarkers and imaging agents for other indications including stroke and neurodegenerative disease. NeuroInsights spoke with CEO Jackson Streeter, MD, who joined the company in February 2010. Dr. Streeter was previously the Founder and CEO of PhotoThera, a company developing a therapeutic laser for treatment of ischemic stroke. It was in that capacity that Streeter went looking for biomarkers, met the founders of Banyan, and became interested in the company...
Companies Covered In This Issue Include: Pfizer, Merck, BioDelivery, Auris, ReNeuron, Bayhill, Johnson & Johnson, Eisai, Repligen, Affiris, Genentech, Vanda, Insys Therapeutics, StemCells, Inc. ExonHit, Impax, CureMark, Amylin, Bayer, Novartis, Novocure, Neurologix, NeuroSearch, Boston Scientific, Lundbeck, Addex, Enteromedics, GlaxoSmithKline, Valeant, Covidien, Bionomics, IntraPace, Ricanto, Targacept. CoLucid, CoAxia, Retina Implant, Oxygen Theraptueeics, Numoda Meiji Seika, Euthymics, NeoVista, Nevro, Prana, Assurex, Arena, Soundcure, toBBB
Subscribe Now:
|
|
